Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Introduction
Classification of Breast Cancer by Type
Non-invasive Breast Cancers
Invasive Breast Cancer
Molecular Subtypes of Breast Cancer
Luminal A
Luminal B Types
HER2 Type
HER2-Amplified
Triple-Negative Breast Cancer (TNBC) or Basal Type
Normal-Like
Brest Cancer Causes, Indications and Risk Factors
Symptoms
Breast Cancer Staging
Epidemiology
United States Breast Cancer Incidence
Chapter 4 Breast Cancer Screening Programs
Introduction
Breast Self-Examination
Clinical Breast Examination
Mammography
Digital Breast Tomosynthesis
Ultrasonography
Magnetic Resonance Imaging (MRI)
BRCA Oncogene Mutations
Chapter 5 Breast Cancer Market Dynamics
Market Drivers
Increasing Incidence of Breast Cancer Worldwide
Market Restraints
Pricing Pressure Experienced by Innovators
High Cost Associated with New Drug Development and Clinical Trials
Regulatory and Reimbursement Hurdles
Market Opportunities
Rising Female Population in Asia Pacific
Increased Demand for Technology Innovation
Technological Advancement in the Drug Sector
Emergence of Breast Cancer Predictive Tests
Patents at the Verge of Expiry
Breast Cancer Therapy: Unmet Needs
Chapter 6 Market Breakdown by Technology
Breast Cancer Diagnostics Market
Technologies
Mammography
Global Mammography Market
Limitations of Mammography
Breast Biopsy Device Market
Introduction
Global Breast Biopsy Device Market
Breast Cancer Predictive Diagnostics market
Introduction
Predictive Diagnostic Tests
Global Breast Cancer Companion Diagnostic Test Market
Chapter 7 Market Breakdown by Drug Class
Overview
Breast Cancer Drug Classes
Breast Cancer Market
Antimetabolites
Taxanes
Aromatase Inhibitors
HER2 Inhibitor
Hormone Therapy
Chapter 8 Market Breakdown by Region
Breast Cancer Incidence by Region
Global Market by Region
North America
Europe
Asia Pacific
Middle East and Africa (MEA)
South America
Chapter 9 Regulatory Scenario
Regulatory Challenges
North America
U.S. Food and Drug Administration (FDA)
Europe
Asia-Pacific
Japan
China
South America
Brazil
Chapter 10 Patent Review/ New Developments
Patent Review
Companion Diagnostics
Patent Expiration
Chapter 11 Reimbursement Landscape
Introduction
United States
Mammography Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drug Reimbursement
Germany
Mammography Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drugs Reimbursement
Mexico
Brazil
Chapter 12 Pipeline Analysis
Introduction
Pipeline by Phase
Phase III
Phase II
Phase I
Pipeline by Company
AbbVie Inc.
Array BioPharma Inc.
AstraZeneca
Belrose Pharmaceuticals
Beta Pharma
BioMarin Pharmaceuticals
CASI Pharmaceuticals Inc.
Celgene
Celldex Therapeutics
Celsion
Clovis
Eli Lilly
Novartis
Pfizer
Puma Biotechnology
Roche
Syndax Pharmaceuticals
Tesaro Inc.
Chapter 13 Competitive Landscape
Major Mammography Equipment Market Players
Major Breast Cancer Drug Market Players
Chapter 14 Company Profiles
ABBVIE INC.
ABBOTT LABORATORIES
ASTRAZENECA PLC
ATOSSA GENETICS INC.
BRISTOL-MYERS SQUIBB CO.
DAKO
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE AG
NANOSTRING TECHNOLOGIES
NOVARTIS INTERNATIONAL AG
PFIZER INC.
PUMA BIOTECHNOLOGY INC.
SANOFI S.A.
Chapter 15 Appendix: Abbreviations



List of Figures


Summary Figure : Global Breast Cancer Diagnostic and Drug Market, by Technology, 2018-2024
Figure 1 : Breast Anatomy of Normal and Cancerous Ducts and Lobules
Figure 2 : Market Shares of Invasive and Non-invasive Breast Cancer, United States, 2017
Figure 3 : Histopathological Classification of Breast Cancer
Figure 4 : Invasive Breast Cancer Market Share, by Type
Figure 5 : Occurrence of Molecular Subtypes Share
Figure 6 : Global Burden of Breast Cancer
Figure 7 : National Cancer Institute Research Funding, 2011-2016
Figure 8 : NCRI Breast Cancer Research Spending, 2009-2017
Figure 9 : Mammography Procedures in U.S., Canada and Mexico, 2010-2015
Figure 10 : Mammography Procedures in Europe, by Country, 2010-2015
Figure 11 : Mammography Procedures in Asia-Pacific, by Country 2010-2015
Figure 12 : Global Mammography Market, 2018-2024
Figure 13 : Global Breast Cancer Drug Market Share, by Drug Class, 2018
Figure 14 : Global Aromatase Inhibitor Drug Market, by Drug Type, 2018-2024
Figure 15 : Global HER2 Inhibitor Drug Market, by Drug Type, 2018-2024
Figure 16 : Global Hormone Receptor Drug Market, by Drug Type, 2018-2024
Figure 17 : Middle East and African Breast Cancer Therapy Market, 2018-2024
Figure 18 : South American Breast Cancer Therapy Market, 2018-2024
Figure 19 : Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 20 : PMDA Medical Device Approval Procedure
Figure 21 : Reimbursement of Drugs in Germany
Figure 22 : Global Market Share of Mammography Equipment, by Company, 2018*
Figure 23 : Global Market Share of Breast Cancer Drugs, by Company, 2018
Figure 24 : AbbVie Inc.: Net Revenue, 2016-2018
Figure 25 : AbbVie Inc.: Lupron Sales, 2016-2018
Figure 26 : Abbott Laboratories: Revenue Share, by Segment, 2018
Figure 27 : Bristol-Myers Squibb Co.: Revenue Share, by Region, 2018
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Business Segment, 2018
Figure 29 : Eli Lilly and Co.: Revenue Share, by Region, 2018
Figure 30 : F. Hoffmann-La Roche Ltd.: Pharmaceutical Revenue Share, by Business Segment, 2018
Figure 31 : F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue, 2016-2018
Figure 32 : F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue Share, by Region, 2018
Figure 33 : Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2018
Figure 34 : Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017

 

List of Tables


Summary Table : Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2024
Table 1 : Difference between Normal and Benign Breast Cancer Cells
Table 2 : New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017
Table 3 : Histological Types, Frequency of Occurrence and Rate of Survival
Table 4 : Mucinous Carcinoma
Table 5 : Steps and Genes Involved in Breast Cancer Metastasis
Table 6 : Molecular Subtypes: Invasive Breast Cancer
Table 7 : Local/Regional Recurrence, by Molecular Subtype
Table 8 : Local/Regional Recurrence, by Molecular Subtype
Table 9 : Local/Regional Recurrence, by Molecular Subtype
Table 10 : Global Breast Cancer Incidence, 2016-2021
Table 11 : Global Breast Cancer Incidence and Mortality, 2018
Table 12 : New Breast Cancer Cases and Mortality (both Sexes), by Region, 2018
Table 13 : New Breast Cancer Cases in the U.S., by Gender, Through 2024
Table 14 : New Female Breast Cancer Cases and Deaths in the U.S., by Age, 2018
Table 15 : Mammography Recommendations
Table 16 : Femara Revenue, 2009-2015
Table 17 : Generic Versions of Letrazole
Table 18 : Global Mammography Market, by Region, Through 2024
Table 19 : Global Mammography Market, by Device Type, Through 2024
Table 20 : Global Breast Cancer Biopsy Device Market, by Region, Through 2024
Table 21 : Breast Cancer Prognostics, Diagnostics, Monitoring and Grading Diagnostics Tests, 2017
Table 22 : Breast Cancer Drugs
Table 23 : Global Breast Cancer Drug Market, by Drug Class, Through 2024
Table 24 : Global Aromatase Inhibitor Drug Market, by Drug Type, Through 2024
Table 25 : Global HER2 Inhibitor Drug Market, by Drug Type, Through 2024
Table 26 : Global Hormone Receptor Drug Market, by Drug Type, Through 2024
Table 27 : Global Breast Cancer Therapy Market, by Region, Through 2024
Table 28 : North American Breast Cancer Therapy Market, by Country, Through 2024
Table 29 : European Breast Cancer Therapy Market, by Country, Through 2024
Table 30 : Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2024
Table 31 : FDA-Approved Drugs, 1996-2019
Table 32 : List of FDA-Approved Companion Diagnostics, 2018
Table 33 : Breast Cancer Drugs Approved by the EMA, 1995-2018
Table 34 : Companion Diagnostics Patent Review, 2015-2017
Table 35 : Breast Cancer Therapeutics Patent Review, 2010-2018
Table 36 : Patent Expiration of Breast Cancer Drugs
Table 37 : Mammography Reimbursement, U.S., 2017
Table 38 : Biopsy Procedure Reimbursement, U.S., 2017
Table 39 : Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
Table 40 : German Mammography In-Patient Reimbursement
Table 41 : In-Patient Biopsy Procedure Codes
Table 42 : Gemzar and Herceptin Reimbursement, Germany, 2017
Table 43 : hase III Breast Cancer Therapy Pipeline
Table 44 : Phase II Breast Cancer Therapy Pipeline
Table 45 : Phase I Breast Cancer Therapy Pipeline
Table 46 : AbbVie Inc.: Pipeline Drugs
Table 47 : Array BioPharma Inc.: Pipeline Drugs
Table 48 : AstraZeneca: Pipeline Drugs
Table 49 : Belrose Pharmaceuticals: Pipeline Drugs
Table 50 : Beta Pharma: Pipeline Drugs
Table 51 : BioMarin Pharmaceuticals: Pipeline Drugs
Table 52 : ASI Pharmaceuticals Inc.: Pipeline Drugs
Table 53 : Celgene: Pipeline Drugs
Table 54 : Celldex Therapeutics: Pipeline Drugs
Table 55 : Celsion: Pipeline Drugs
Table 56 : Clovis: Pipeline Drugs
Table 57 : Eli Lilly: Pipeline Drugs
Table 58 : Novartis: Pipeline Drugs
Table 59 : Pfizer Inc.: Pipeline Drugs
Table 60 : Puma Biotechnology: Pipeline Drugs
Table 61 : Roche: Pipeline Drugs
Table 62 : Syndax Pharmaceuticals: Pipeline Drugs
Table 63 : Tesaro Inc.: Pipeline Drugs
Table 64 : AbbVie Inc.: Company Net Revenue, 2016-2018
Table 65 : Abbott Laboratories: Company Net Revenue, 2016-2018
Table 66 : Abbott Laboratories: Marketed Products, 2018
Table 67 : AstraZeneca PLC: Company Net Revenue, 2016-2018
Table 68 : AstraZeneca PLC: Marketed Products, 2018
Table 69 : Bristol-Myers Squibb Co.: Net Revenue, 2016-2018
Table 70 : Eli Lilly and Co.: Net Revenue, 2016-2018
Table 71 : F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2016-2018
Table 72 : Novartis International AG: Net Revenue, by Segment, 2016-2018
Table 73 : Pfizer Inc.: Net Revenue, 2016-2018
Table 74 : Abbreviations Used in Breast Cancer Diagnostic and Drug Technology